2022

• Tyligand Announces First Patient Dosed for Phase 1 Trial of TSN084, A Multi-Kinase Inhibitor to Address Tumor Resistance of Targeted Therapies
• Tyligand Bioscience Receives IND Clearance from China NMPA for TSN084, a Multi-kinase Inhibitor to Address Tumor Resistance to Targeted Therapies
• Tyligand Bioscience was recognized in the first KPMG China 2021 Biotechnology Innovation 50 Enterprises